Mengjun Shu

Title: Innovations of Mengjun Shu in Antibody Development

Introduction

Mengjun Shu is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic use. His work focuses on enhancing the efficacy of treatments for HER2 positive tumors.

Latest Patents

Mengjun Shu holds a patent for a mutated antibody of the fully humanized HER2 antibody, specifically GB235-019. This invention includes the amino acid sequences of the heavy and light chain variable regions, which are crucial for the antibody's functionality. The mutated antibody is designed to specifically bind to the human HER2 antigen, similar to the original GB235-019 antibody. This innovation has potential applications in combination therapies for treating HER2 positive tumors, as well as weakly positive or negative tumors.

Career Highlights

Mengjun Shu is currently associated with Genor Biopharma Co., Ltd., where he continues to advance his research in antibody development. His work is pivotal in the ongoing efforts to improve cancer therapies and patient outcomes.

Collaborations

Mengjun Shu collaborates with esteemed colleagues, including Qing Zhou and Zhuzi He, to further enhance the research and development of innovative therapeutic agents.

Conclusion

Mengjun Shu's contributions to the field of biotechnology, particularly through his patented innovations, highlight the importance of research in developing effective cancer treatments. His work exemplifies the potential of mutated antibodies in advancing medical science.